Historically, CD19/CD5 co-expression with demonstration of clonality by Ig light chain (κ or λ) restriction has been the simplest and most commonly used FCM approach for MRD evaluation, virtually applicable to all CLL cases but with a low sensitivity. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.